苏洋投资已减持奥赛康1016万股

Core Viewpoint - Jiangsu Suyang Investment Co., Ltd. has reduced its stake in Aosaikang Pharmaceutical Co., Ltd. by 10,160,232 shares, representing 1.09% of the total share capital, from February 27, 2025, to September 12, 2025, due to its own operational needs [2][3]. Group 1: Shareholding Changes - Jiangsu Suyang Investment's shareholding decreased from 14.00% to 12.91%, triggering a 1% change in equity [3]. - The reduction was executed through centralized bidding and block trading, in accordance with a previously disclosed reduction plan [3]. Group 2: Impact on Aosaikang - The share reduction will not lead to a change in control of Aosaikang, and the management team remains stable [4]. - Aosaikang will continue to focus on its established strategy in pharmaceutical research, production, and sales, ensuring the provision of quality medicines to the market [4]. Group 3: Financial Performance - Aosaikang reported a revenue of 1.007 billion yuan for the first half of 2025, reflecting a year-on-year growth of 9.20% [5]. - The net profit attributable to shareholders reached 160 million yuan, marking a significant year-on-year increase of 111.64% [5].